论文部分内容阅读
目的探讨术前行新辅助治疗(包括新辅助放化疗和新辅助化疗)联合外科手术治疗中晚期食管癌的可行性和安全性。方法ⅢA-ⅢC期局部中晚期食管鳞癌患者11例(A组),术前完成多西他赛+顺铂方案的新辅助化疗,同期给予常规分割剂量放疗;然后行食管癌切除术。选择病情相当,单纯接受手术治疗的的20例患者(B组)作对照,比较两组的疗效。结果 A组手术时间、术中出血量和淋巴结转移枚数均少于B组[(233.6±19.9)min vs.(257.3±28.9)min、(160.9±36.4)ml vs.(216.5±56.4)ml和(1.3±0.9)枚vs.(2.3±1.4)枚](P<0.05)。结论新辅助治疗联合外科手术治疗中晚期食管癌安全可行,近期临床疗效确切。
Objective To investigate the feasibility and safety of neoadjuvant therapy (including neoadjuvant chemoradiation and neoadjuvant chemotherapy) combined with surgical treatment of advanced esophageal cancer before operation. Methods A total of 11 patients with stage ⅢA-ⅢC advanced esophageal squamous cell carcinoma (A group) were treated with neoadjuvant chemotherapy of docetaxel and cisplatin before surgery. The patients were treated with conventional fractionated radiotherapy at the same period, and then esophageal resection was performed. Twenty patients (B group) with similar disease and simple surgery were selected as controls to compare the curative effect of the two groups. Results The operation time, intraoperative blood loss and lymph node metastasis in group A were less than those in group B [(233.6 ± 19.9) min vs. (257.3 ± 28.9) min, (160.9 ± 36.4) ml vs. (216.5 ± 56.4) (1.3 ± 0.9) pieces vs. (2.3 ± 1.4) pieces] (P <0.05). Conclusion Neo-adjuvant therapy combined with surgical treatment of advanced esophageal cancer safe and feasible, the recent clinical curative effect is accurate.